The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 4, 2008, Pages 226-237

  Wright, John W ^a   Harding, Joseph W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

ACE inhibitors; Alzheimer's disease; Angiotensin II; Angiotensin IV; Angiotensin receptor blockers; AT1 receptor; AT4 receptor; Dementia; Renin angiotensin system

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CERANAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIVALINAL ANGIOTENSIN IV; DONAZEPIL; DONEPEZIL; ENALAPRIL; GINKGO BILOBA EXTRACT; HYDROCHLOROTHIAZIDE; LEUCYLVALYLVALYLHEMORPHIN 7; LOSARTAN; LOSARTAN POTASSIUM; MENAMTINE; NERVE GROWTH FACTOR; PLACEBO; PROTEIN C FOS; RIVASTIGMINE; UNCLASSIFIED DRUG; AT4 RECEPTOR;

ADD ON THERAPY; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EXPERIMENTAL MODEL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HIPPOCAMPUS; HORMONE RELEASE; HUMAN; HYPERTENSION; LONG TERM POTENTIATION; MAZE TEST; MEMORY CONSOLIDATION; MILD COGNITIVE IMPAIRMENT; MUSCLE CRAMP; NONHUMAN; PASSIVE AVOIDANCE; PASSIVE MOVEMENT; PROTEIN DEGRADATION; RECEPTOR BLOCKING; SLEEP DISORDER; SPATIAL MEMORY; SYNAPSE; TREATMENT DURATION; COGNITION; DEMENTIA; DRUG ANTAGONISM; MEMORY DISORDER; REVIEW;

ALZHEIMER DISEASE; COGNITION; DEMENTIA; DRUG APPROVAL; HUMANS; MEMORY DISORDERS; RECEPTORS, ANGIOTENSIN;

EID: 66149108067     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320308099084     Document Type: Article

References (140)

1. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
2. Clark CM Clinical manifestations and diagnostic evalulation of patients with Alzheimer's disease. In: Clark CM and Trajanowski JQ (eds.). Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. New York: McGraw-Hill, 2000;95-114.
3. Zec RF, Trivedi MA The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: A critical and theoretical review. Neuropsychol Rev 2002;12:65-109.
4. Doody R., Dunn J., Clark CM et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001;12:295-330.
5. Salloway S., Ferris S., Kluger A. et al. Efficacy of donepezil in mild cognitive impairment: A randomized, placebo-controlled trial. Neurology 2004;63:651-7.
6. Petersen RC, Thomas RG, Grundman M. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379 - 88.
7. Doraiswamy M., Xiong GL Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 2006;7:1-10.
8. Topper R., Gehrmann J., Banati R. et al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain inury. Acta Neuropathol 1995;89:23-8.
9. Seif EI, Nasr M., Peruche B. et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990;185:19-24.
10. Miguel-Hidalgo JI, Alvarex XA, Cacabelos R., Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res 2002;958:210-21.
11. Danysz W. CX-516 Cortex pharmaceuticals. Curr Opin Investig Drugs 2002;3:1081-8.
12. Jourdi H., Yanagihara T., Martinez U. et al. Effects of positive AMPA receptor modulators on calpain-mediated spectrin degradation in cultured hippocampal slices. Neurochem Int 2005;46:31-40.
13. Francis PT Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease. Neurodegener Dis 2008;5:241-3.
14. Bliss TV, Gerner-Medwin AR Long-lasting potentiation of synaptic transmission in the dentate area of the unanesthetized rabbit following stimulation of the perforant path. J Physiol 1973;232:357-74.
15. Bliss TV, Lomo T. Long-term potentiation of synaptic transmission in the dentate area of the anesthetized rabbit following stimulation of the perforant path. J Physiol 1973;232:331-56.
16. Lynch G., Rex CS, Gall CM LTP consolidation: Substrates, explanatory power, and functional significance. Neuropharmacology 2007;52:12- 23.
17. Wright JW, Yamamoto BJ, Harding JW Angiotensin receptor subtype mediated physiologies and behaviors: New discoveries and clinical targets. Prog Neurobiol 2008;84:157-81.
18. Malenka RC, Bear MF LTP and LTD: An embarrassment of riches. Neuron 2004;44:5-21.
19. Wezenberg E., Verkes RJ, Ruigt GS et al. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007;32:1272-83.
20. McGeer PL, McGeer EG Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging 2001;22:799-809.
21. Leuchtenberger S., Maler J., Czirr E. et al. Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein. Neurodegener Dis 2008;(In press).
22. Sainati SM, Ingram DM, Talwalker S. et al. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. 6th International Stockholm/ Springfield Meeting on Advances in Alzheimer Therapy, 5-8 April 2000, Stockholm, Sweden.
23. Aisen PS, Schafer KA, Grundman M. et al. Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression. JAMA 2003;289:2819-26.
24. Winblad B., Palmer K., Kivipelto M. et al. Mild cognitive impairment - beyond controversies, toward a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-6.
25. Ezoulin MJ, Liu Z., Dutertere-Catella H. et al. A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. Int Immunopharmacol 2007;7:1685-94.
26. Sparks DL, Martin TA, Gross DR et al. Link between heart disease, cholesterol, and Alzheimer's disease: A review. Microsc Res Tech 2000;50:287-90.
27. de la Torre JC Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 2002;977:196-215.
28. de la Torre JC How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 2006;28:637-44.
29. Benedict RH Cognitive function after open-heart surgery: Are postoperative neuropsychological deficits caused by cardiopulmonary bypass? Neuropsychol Rev 1994; 4: 223 - 55.
30. Brown WR, Moody DM, Tytell M. et al. Microembolic brain injuries from cardiac surgery: Are they seeds of future Alzheimer's disease? Ann N Y Acad Sci 1997;826:386-9.
31. Caplan I. Protecting the brains of patients after heart surgery. Arch Neurol 2001;58:549-50.
32. Raja PV, Blumenthal JA, Doraiswamy PM Cognitive deficits following coronary artery bypass grafting: Prevalence, prognosis, and therapeutic strategies. CNS Spectr 2004;9:763-72.
33. Forette F., Seux MI, Staessen JA et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Sys-Eur) study. Arch Intern Med 2002;162:2046-52.
34. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-75.
35. Fox NC, Black RS, Gilman S. et al. Effects of A immunization (AN1792) on MRI measures of cerebral volume in Alzheimer's disease. Neurology 2005;64:1563-72.
36. Oken BS, Storzbach DM, Kaye JA The efficacy of ginkgo biloba on cognitive function in Alzheimer's disease. Arch Neurol 1998;55:1409-15.
37. Wettstein A. Cholinesterase inhibitors and ginkgo extracts: Are they comparable in the treatment of dementia? Phytomedicine 2000;6:393-401.
38. Van Dongen MV, Rossum EV, Kessels A. et al. Ginkgo for elderly people with dementia and age-associated memory impairment: A randomized clinical trial. J Clin Epidemiol 2003;56:367-76.
39. Burns NR, Bryan J., Nettelbeck T. Ginkgo biloba: No robust effect on cognitive abilities or mood in healthy young or older adults. Hum Psychopharmacol 2006;21:27-37.
40. Birks J., Grimley Evans J., Lee H. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2007;18:CD003120.
41. Bae CY, Cho CY, Cho K. et al. A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000;48:1566-71.
42. Rüther E., Ritter R., Apecechea M. et al. Sustained improvement in patients with dementia of Alzheimer's type (DAT) 6 months after termination of cerebrolysin therapy. J Neural Transm 2002;107:815-29.
43. Lonn E., Bosch J., Yusuf S. et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005;293:1338-47.
44. Johnston CI Biochemistry and pharmacology of the renin-angiotensin system. Drugs 1990; 39: 21 - 31.
45. Vauquelin G., Michotte Y., Smolders I. et al. Cellular targets for angiotensin II fragments: Pharmacological and molecular evidence. J Renin Angiotensin Aldosterone Syst 2002;3:195-204.
46. Speth RC, Brown TE, Barnes RD, Wright JW Brain angiotensinergic activity: The state of our current knowledge. Proc West Pharmacol Soc 2003;46:11-15.
47. Stragier B., Bundel DD, Sarre S. et al. Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: A review. Heart Fail Rev 2008;13:321-337.
48. de Gasparo M., Catt KJ, Inagami T. et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
49. Ferrario CM Role of angiotensin II in cardiovascular disease - therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006;7:3-14.
50. Glossmann H., Baukal A., Catt KJ Angiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides. J Biol Chem 1974;249:664-6.
51. Bennett JP Jr, Snyder SH Angiotensin II binding to mammalian brain membranes. J Biol Chem 1976;251:7423-30.
52. Harding JW, Cook VI, Miller-Wing AV et al. Identification of an AII (3-8) AIV binding site in guinea pig hippocampus. Brain Res 1992;583:340-3.
53. Swanson GN, Hanesworth JM, Sardinia MF et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992;40:409-19.
54. 2 recognition sites in bovine adrenal cortex. Eur J Pharmacol 1992;19:319-22.
55. Bernier SG, Fournier A., Guillemette G. A specific binding site recognizing a fragment of angiotensin II in bovine adrenal cortex membranes. Eur J Pharmacol 1994; 271: 55 - 63.
56. Santos RA, Campagnole-Santos MJ, Andrade SP Angiotensin(1-7): An update. Regul Pept 2000;91:45-62.
57. Mustafa T., Lee JH, Chai SY et al. Bioactive angiotensin peptides: Focus on angiotensin IV. J Renin Angiotensin Aldosterone Syst 2001;2:205-10.
58. Ferrario CM Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Curr Hypertens Rep 2003;5:129-34.
59. Neves LA, Averill DB, Ferrario CM et al. Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides 2003;24:455-62.
60. Wright JW, Krámar EA, Meighan SE, Harding JW Extracellular matrix molecules, long-term potentiation, memory consolidation and the brain angiotensin system. Peptides 2002;23:221-46.
61. Wright JW, Harding JW The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol 2004;72:263-93.
62. Wright JW, Harding JW Important roles for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Rev 1997;25:96-124.
63. Kehoe PG, Wilcock GK Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007;6:373-8.
64. Kramkowski K., Mogielnicki A., Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006;4:529-39.
65. Ellul J., Archer N., Foy CM et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 2006;78:233-9.
66. Croog SH, Levine S., Testa MA et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-74.
67. Deicken RF Captopril treatment of depression. Biol Psychiatry 1986;12:1425-8.
68. Zubenko GS, Nixon RA Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984;141:110-11.
69. Barnes JM, Barnes NM, Costall B. et al. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol 1992;19(suppl 6):S63-S71.
70. Bartus RT, Dean RL, Beer B., Lippa AS The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
71. Barnes NM, Champaneria S., Costall B. et al. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1990;1:239-42.
72. Costall B., Coughlan J., Horovitz ZP et al. The effects of ACE inhibitors captopril and SQ29852 in rodent tests of cognition. Pharmacol Biochem Behav 1989;33:573-9.
73. Morris RG Development of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
74. Barnes NM, Cheng CH, Costall B. et al. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 1991;20:289-92.
75. Barnes NM, Costall B., Egli P. et al. Characterization of [3H]ceranapril recognition sites in rat and human brain tissue. Neuropharmacology 1991;30:907-14.
76. Barnes JM, Barnes NM, Costall B. et al. ACE inhibition and cognition. In: MacGregor GA and Sever PS (eds.). Current Advances in ACE Inhibition. New York: Churchill Livingston Press,1989;159-71.
77. Mondadori C., Etienne P. Nootropic effects of ACE inhibitors in mice. Psychopharmacology 1990;100:301-07.
78. Flood JF, Morley JE Dose-response differences in the ability of ramipril to improve retention in diabetic mice. Eur J Pharmacol 1993;240:311-14.
79. Barnes NM, Costall B., Kelly ME et al. Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. Neuroreport 1991;2:351-3.
80. DeNoble VJ, DeNoble KF, Spencer KR et al. Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: Effect on a renin-induced deficit of a passive avoidance response in rats. Brain Res 1991;561:230-5.
81. Chen BZ, Mendelsohn FAO. Effect of acute and chronic administration of ceranapril on angiotensin converting enzyme in plasma, kidney, lung, brain regions and cerebrospinal fluid of rats. Neuropharmacology 1992;31:929-35.
82. Manschot SM, Biessels GJ, Cameron NE et al. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res 2003;966:274-82.
83. Wyss JM, Kadish I., van Groen T. Age-related decline in spatial learning and memory: Attenuation by captopril. Clin Exp Hypertens 2003;25:455-74.
84. Jenkins TA, Chai SY Effect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats. Neurobiol Learn Mem 2007;87:218-24.
85. Amenta F., Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: Evidence from pre-clinical and clinical studies. Clin Exp Hypertens 2002;24:697-713.
86. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
87. Rozzini L., Chilovi BV, Vertoletti E. et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2006;21:550-5.
88. Poon IO Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008;28:366-75.
89. Hajjar IM, Keown M., Lewis P., Almor A. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: An observational study. Am J Alzheimers Dis Other Demen 2008;23:77-83.
90. Hu J., Igarashi A., Kamata M., Nakagawa H. Angiotensin converting enzyme degrades Alzheimer amyloid beta-peptide (A beta): Retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity. J Biol Chem 2001;276:47863-8.
91. Oba R., Igarashi A., Kamata M. et al. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005;21:733-40.
92. Hemming ML, Selkoe DJ Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005;280:37644-50.
93. Kehoe PG, Russ C., McIlory S. et al. Variation in DCP1 encoding ACE is associated with susceptibility to Alzheimer disease. Nat Genet 1999;21:71-2.
94. Kehoe PG The renin-angiotensin-aldosterone system and Alzheimer's disease? J Renin Angiotensin Aldosterone Syst 2003;4:80-93.
95. Kehoe PG, Katzov H., Feuk L. et al. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet 2003;12:859-67.
96. Wright JW, Harding JW Angiotensins in brain function. In: Lim R (ed.). Handbook of Neurochemistry and Molecular Neurobiology: Neuroactive Proteins and Peptides. New York: Springer Science Publications, 2006;627-53.
97. Carson JA, Turner AJ Beta-amyloid catabolism: Roles for heprilysin (NEP) and other metallopeptidases? J Neurochem 2002;81:1-8.
98. Gard PR Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 2004;8:7-14.
99. Lee J, Chai SY, Mendelsohn FA et al. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001;40:618-23.
100. Gard PR, Rusted M. Angiotensin and Alzheimer's disease: Therapeutic prospects. Expert Rev Neurother 2004;4:87-96.
101. Tedesco MA, Ratti G., Mennella S. et al. Comparison of losartan and hydroclorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130-4.
102. Fogari R., Preti P., Mugellini A. et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens 2002;15:36A.
103. Hansson L., Lithell H., Skoog I. et al. Cognition and prognosis in the elderly (SCOPE). Blood Press 1999;8:177-83.
104. Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE) - recent analyses. J Hypertens 2006;24(suppl 1):S107-14.
105. Zanchetti A., Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. Blood Press 2006;15:71-9.
106. Birkenhäger WH, Staessen JA Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog Cardiovasc Dis 2006;49:1-10.
107. Hanes DS, Weir MR Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol 2007;16:175-82.
108. Wang JM, Boudhuin P., Courtoy PJ, de Potter WP Conversion of angiotensin II into active fragments by an endosomal pathway in bovine adrenal medullary cells in primary culture. Endocrinology 1995;136:5274-82.
109. Gáborik Z., Szaszák M., Szidonya L. et al. -arrestin and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Mol Pharmacol 2001;59:239-47.
110. Dale JB, Seachrist JL, Banwah AV et al. Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7, and Rab11 GTPases. J Biol Chem 2004;279:13110-18.
111. Kramár EA, Armstrong DL, Ikeda S. et al. The effects of angiotensin IV on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 2001;897:114-21.
112. Wayner MJ, Armstrong DL, Phelix CF et al. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001;22:1403-14.
113. Wayner MJ, Polan-Curtain JL, Armstrong DL Dose and time dependency of angiotensin II inhibition of hippocampal long-term potentiation. Peptides 1995;16:1079-82.
114. 4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation. Neuroscience 2006;137:1369-79.
115. Braszko JJ, Kupryszewski G., Witczuk B., Wisniewski K. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and conditioned avoidance responses in rats. Neuroscience 1988;27:777-83.
116. Braszko JJ, Wlasienko J., Koziolkiewicz W. et al. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties. Brain Res 1991;542:49-54.
117. Wright JW, Miller-Wing AV, Shaffer MJ et al. Angiotensin II(3-8) [ANG IV] hippocampal binding: Potential role in the facilitation of memory. Brain Res Bull 1993;32:497-502.
118. Wright JW, Krebs LT, Stobb JW, Harding JW The angiotensin IV system: functional implications. Front Neuroendocrinol 1995;16:23-52.
119. Wright JW, Stubley L., Pederson ES et al. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999;19:3952-61.
120. Stubley-Weatherly LA, Harding JW, Wright JW. Effects of discrete kainic acid-induced hippocampal lesions on spatial and contextual learning and memory. Brain Res 1996;716:29-38.
121. Pederson ES, Harding JW, Wright JW. Attenuation of scopolamine-induced spatial learning impairments by an angioensin IV analog. Regul Pept 1998;74:97-103.
122. 4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Pept 2001;102:147-56.
123. Olson ML, Olson EA, Qualls JH et al. Norleucine1angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 2004;25:233-41.
124. Roberts KA, Krebs LT, Kramár EA et al. Autoradiographic identification of brain angiotensin IV binding sites and differential c-fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Brain Res 1995;682:13-21.
125. Zhu B., Herbert J. Central antagonism of atrial natriuretic peptides on behavioral and hormonal responses to angiotensin II: Mapping with c-fos. Brain Res 1996;734:55-60.
126. 4 receptor ligands, Nle1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004;24:341-9.
127. Albiston AL, Peck GR, Yeatman HR et al. Therapeutic targeting of insulin-regulation aminopeptidase: Head and tails? Pharmacol Ther 2007;116:417-27.
128. Chai SY, Fernando R., Peck G. et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004;61:2728-37.
129. 4 and their functions. Regul Pept 1995;59:269-95.
130. Basso N., Paglia N., Stella I. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005;128:247-52.
131. Hajjar IM, Keown M., Frost B. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction. Curr Hypertens Rep 2005;7:466-73.
132. Khachaturian AS, Zandi PP, Lyketsos CG et al. Antihypertensive medication use and incident Alzheimer disease. Arch Neurol 2006;63:686-92.
133. Braszko JJ, Walesiuk A., Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J Renin Angiotensin Aldosterone Syst 2006;7:168-74.
134. 4 receptor) in the human forebrain, midbrain and pons as visualized by in vitro receptor autoradiography. J Chem Neuroanat 2000;20:339-48.
135. Gard PR The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002;438:1- 14.
136. Meighan SE, Meighan PC, Choudhury P. et al. Effects of extracellular matrix-degrading proteases matrixmetalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem 2006;96:1227-41.
137. Meighan PC, Meighan SE, Davis CJ et al. Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses. J Neurochem 2007;102:2085-96.
138. Stragier B., Sarre S., Vanderheyden P. et al. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J Neurochem 2004;90:1251-7.
139. 4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J Pharmacol Exp Ther 2003;305:205-11.
140. Andersson H., Demaegdt H., Vauquelin G. et al. Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem 2008;16:6924-35.